Development and Evaluation of Metformin HCL Injectable Controlled-Release Hydrogel for The Management of Diabetes

Abstract

Chronic metabolic condition called diabetes mellitus causes high blood glucose levels as a result of poor glucose control. Metformin is one of the main oral antidiabetic drugs used in current treatment strategies for diabetes control. These techniques, meanwhile, frequently run into problems with patient compliance, dose optimisation, and systemic adverse effects. Controlled-release drug delivery systems have attracted a lot of interest because they provide prolonged and localized drug release, boosting therapeutic efficacy while reducing side effects, to overcome these constraints. Injectable hydrogels offer potential as vehicles for controlled drug delivery because of their biocompatibility, customizable characteristics, and capacity to hold and release therapeutic molecules. It was noted that the formulations (F6 to F11) contained between 96.3% and 98.90% of the medication. A study of the formulation's medication content showed a 99.97% purity rate. Investigations were also done on the hydrogel's biocompatibility. The produced hydrogel's IR spectra have shown that a cross-linking network exists between the injected components.